Articles
DSCSA one-month countdown
From 27 November 2018, the Drug Supply Chain Security Act (DSCSA) will be actively enforced by regulators in the US. Here, leaders from across the pharmaceutical sector discuss the industry’s readiness and what companies should be...
Articles
Is the market now DSCSA ready?
Roundtable questionsIn November 2017, the pharma industry was granted an extension of the Drug Supply Chain Security Act (DSCSA) enforcement date to November 2018. Regulators told the market that they would not actively enforce the new serialization requirements until...
Articles
35 is the danger zone for hearts
We normally associate heart disease with old age. Doctors have been warning that the average age of first heart attacks has been coming down due to multiple factors like sedentary lifestyles, fast food and increased smoking and drinking. ...
Articles
DSCSA: The time has come to Act
Thierry Protas, Global Pharma Director at Videojet Technologies, looks at the importance of the Drug Supply Chain Security Act (DSCSA) legislation, the looming 2018 cut off point for compliance, and how coding and marking is a key consideration.
On 27...
Articles
Quicker, More Accurate Diagnoses for Dangerous Diseases and Genetic Disorders
Standfirst:There is growing awareness of the valuable role that diagnostics can play, both in the early identification and treatment of dangerous or infectious diseases as well as genetic disorders.
The early and accurate identification of one’s predisposition to cancer, sexually...
Articles
Dash to Serialization Implementation: The European Falsified Medicines Directive (FMD) Countdown for Indian Pharma Manufacturers
Compliance is a serious issue for India’s pharmaceutical manufacturers, distributors, and retailers; due to the complicated nature of the pharmaceutical supply chain. Serialization requires pharmaceutical manufacturers to invest in new technology and adapt their current processes and systems.
Not only...
Articles
Looking Towards the Future: Worldwide Biosimilar Uptake and Pricing
What is a biosimilar?
Whereas generic drugs are identical copycats of small-molecule chemical products, biosimilars are only similar to biologic products; innately more complex than chemical products, biologics are large-molecule, organic drugs, subject to natural variability and vulnerability due to...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read